Paul Stephen Unger MD
Breast Cancer, Hematologic Oncology
Champlain Valley Hematology Oncology
Join to View Full Profile
111 Colchester AveBurlington, VT 05401
Phone+1 802-847-8400
Fax+1 802-655-9170
Dr. Unger is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Paul Unger is an Oncologist based in Burlington, VT, with a focus on breast cancer and hematologic oncology. He completed his fellowship in Hematology and Medical Oncology at Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer Institute and his Residency in Internal Medicine at New York Presbyterian Hospital (Cornell Campus). He's an alumnus of Harvard Medical School, Class of 1986. Dr. Unger has contributed to key oncology research, with publications in the Journal of Clinical Oncology and Supportive care in cancer. He has been recognized by the American College of Physicians as a Fellow (FACP) in 2006
Education & Training
Mass General Brigham/Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 1989 - 1992
New York Presbyterian Hospital (Cornell Campus)Residency, Internal Medicine, 1986 - 1989
Harvard Medical SchoolClass of 1986
Certifications & Licensure
VT State Medical License 1990 - 2026
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification OncoEMR, Altos Solutions, Inc., 2011-2012
- Fellow (FACP) American College of Physicians, 2006
Clinical Trials
- Neoadjuvant Cisplatin/Docetaxel (CDDP/TXT) and Chemoradiation for Head and Neck Cancer Start of enrollment: 2009 Sep 01
- Evaluation of Loratadine for Prevention of Pegfilgrastim-Induced Pain Start of enrollment: 2011 May 01
Publications & Presentations
PubMed
- 35 citationsChemotherapy and Targeted Therapy for Patients With Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer That is Either Endocrine-Pretreated or H...Beverly Moy, R. Bryan Rumble, Steven E. Come, Nancy E. Davidson, Angelo Di Leo
Journal of Clinical Oncology. 2021-07-29 - 22 citationsRandomized phase II study of loratadine for the prevention of bone pain caused by pegfilgrastimJulia Moukharskaya, D M Abrams, Takamaru Ashikaga, Farrah B. Khan, Joanna Schwartz
Supportive Care in Cancer. 2016-02-19
Professional Memberships
- Member
- Member
- Fellow
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
